Lista de obras -

90Y-ibritumomab tiuxetan radiotherapy as first-line therapy for early stage low-grade B-cell lymphomas, including bulky disease

artículo científico publicado en 2014

A Prospective Trial of Radiation Therapy Efficacy and Toxicity for Localized Mucosa-associated Lymphoid Tissue (MALT) Lymphoma

scientific article published on 09 December 2020

A phase 1 trial of alisertib and romidepsin for relapsed/refractory aggressive B-cell and T-cell lymphomas

scientific article published on 09 May 2019

A phase I study of romidepsin and ifosfamide, carboplatin, etoposide for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma

artículo científico publicado en 2018

Additional therapy improves outcomes in completely resected, limited-stage follicular lymphoma

artículo científico publicado en 2019

Autologous Stem Cell Transplantation for Large B-cell Lymphoma with Secondary Central Nervous System Involvement

Autologous stem cell transplantation for untreated transformed indolent B-cell lymphoma in first remission: an international, multi-centre propensity-score-matched study

artículo científico publicado en 2020

CCL3 and CCL4 are biomarkers for B cell receptor pathway activation and prognostic serum markers in diffuse large B cell lymphoma

artículo científico publicado en 2015

Characteristics and management of rash following lenalidomide and rituximab in patients with untreated indolent non-Hodgkin lymphoma

artículo científico publicado en 2015

Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas

artículo científico publicado en 2020

Characteristics, management, and outcomes of patients with follicular dendritic cell sarcoma.

artículo científico publicado en 2017

Clinical and radiologic correlates of neurotoxicity after axicabtagene ciloleucel in large B-cell lymphoma

artículo científico publicado en 2020

Clinicopathological characteristics, outcomes and pattern of mutations in patients with follicular lymphoma who progressed on Bruton tyrosine kinase inhibitors.

artículo científico publicado en 2017

De novo CD5+ diffuse large B-cell lymphoma, NOS: clinical characteristics and outcomes in rituximab era

artículo científico publicado en 2019

Dose adjusted-EPOCH-R and mediastinal disease may improve outcomes for patients with gray-zone lymphoma

artículo científico publicado en 2016

Dose-Adjusted EPOCH-R and Mid-Cycle High Dose Methotrexate for Patients with Systemic Lymphoma and secondary CNS Involvement.

artículo científico publicado en 2016

Double hit lymphoma: the MD Anderson Cancer Center clinical experience.

artículo científico publicado en 2014

Early Stage Extranodal Follicular Lymphoma: Characteristics, Management, and Outcomes

scientific article published on 26 February 2019

Efficacy of venetoclax in high risk relapsed mantle cell lymphoma (MCL) - outcomes and mutation profile from venetoclax resistant MCL patients

scientific article published on 02 April 2020

Encouraging activity for R-CHOP in advanced stage nodular lymphocyte-predominant Hodgkin lymphoma

artículo científico publicado en 2017

Experience with HSP90 inhibitor AUY922 in patients with relapsed or refractory non-Hodgkin lymphoma

artículo científico publicado en 2015

Favorable outcomes with de-escalated radiation therapy for limited-stage nodular lymphocyte-predominant Hodgkin lymphoma

scientific article published on 01 May 2019

Four-year follow-up of a single arm, phase II clinical trial of ibrutinib with rituximab (IR) in patients with relapsed/refractory mantle cell lymphoma (MCL)

artículo científico publicado en 2018

Frontline antibiotic therapy for early-stage Helicobacter pylori-negative gastric MALT lymphoma

scientific article published on 06 March 2019

Genomic profiles and clinical outcomes of de novo blastoid/pleomorphic MCL are distinct from those of transformed MCL

scientific article published on 01 March 2020

Hematopoietic recovery and immune reconstitution after axicabtagene ciloleucel in patients with large B-cell lymphoma

scientific article published on 30 July 2020

High ten-year remission rates following rituximab, fludarabine, mitoxantrone and dexamethasone (R-FND) with interferon maintenance in indolent lymphoma: Results of a randomized Study

artículo científico publicado en 2017

Hitting a Moving Target: Successful Management of Diffuse Large B-cell Lymphoma Involving the Mesentery With Volumetric Image-guided Intensity Modulated Radiation Therapy

artículo científico publicado en 2018

Impact of Donor Type and Melphalan Dose on Allogeneic Transplantation Outcomes for Patients with Lymphoma

scientific article published on 11 February 2019

Impact of histologic subtypes and treatment modality among patients with primary central nervous system lymphoma: a SEER database analysis.

artículo científico publicado en 2018

Impact of maintenance rituximab in patients with de novo transformed indolent B cell lymphoma

artículo científico publicado en 2020

Initial report of a phase II study with R-FND followed by ibritumomab tiuxetan radioimmunotherapy and rituximab maintenance in patients with untreated high-risk follicular lymphoma

artículo científico publicado en 2020

Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial

artículo científico publicado en 2012

Lenalidomide plus rituximab (R2 ) in previously untreated marginal zone lymphoma: subgroup analysis and long-term follow-up of an open-label phase 2 trial

scientific article published on 28 March 2019

Lenalidomide, idelalisib, and rituximab are unacceptably toxic in patients with relapsed/refractory indolent lymphoma.

artículo científico publicado en 2015

Limited stage grade 3 follicular lymphoma patients can experience favorable outcomes with combined modality therapy

scientific article published on 03 April 2019

Long Term Follow-Up of Lenalidomide and Rituximab as Initial Treatment of Follicular Lymphoma

scientific article published on 15 September 2020

Long-Term Remissions of Patients With Follicular Lymphoma Grade 3 Treated With R-CHOP.

artículo científico publicado en 2017

Long-term outcomes and mutation profiling of patients with mantle cell lymphoma (MCL) who discontinued ibrutinib

scientific article published on 02 September 2018

Management strategies and outcomes for very elderly patients with diffuse large B-cell lymphoma.

artículo científico publicado en 2016

Maternal and Fetal Outcomes After Therapy for Hodgkin or Non-Hodgkin Lymphoma Diagnosed During Pregnancy.

artículo científico publicado en 2016

Nonmyeloablative allogeneic transplantation with or without 90yttrium ibritumomab tiuxetan is potentially curative for relapsed follicular lymphoma: 12-year results.

artículo científico publicado en 2012

Outcomes After Reduced-Dose Intensity Modulated Radiation Therapy for Gastric Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma

scientific article published on 12 February 2019

Paclitaxel, topotecan and rituximab: long term outcomes of an effective salvage programme for relapsed or refractory aggressive B-cell non-Hodgkin lymphoma

scientific article published on 08 July 2014

Pegylated liposomal doxorubicin replacing conventional doxorubicin in standard R-CHOP chemotherapy for elderly patients with diffuse large B-cell lymphoma: an open label, single arm, phase II trial

artículo científico publicado en 2014

Phase 2 trial of bortezomib in combination with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with bortezomib, rituximab, methotrexate, and cytarabine for untreated mantle cell lymphoma.

artículo científico publicado en 2018

Phase I study of panobinostat plus everolimus in patients with relapsed or refractory lymphoma

artículo científico publicado en 2013

Phase II study of HCVIDD/MA in patients with newly diagnosed peripheral T-cell lymphoma

artículo científico publicado en 2015

Phase II study of an AKT inhibitor MK2206 in patients with relapsed or refractory lymphoma

artículo científico publicado en 2015

Phase-I and randomized phase-II trial of panobinostat in combination with ICE (ifosfamide, carboplatin, etoposide) in relapsed or refractory classical Hodgkin lymphoma.

artículo científico publicado en 2017

Pre-treatment maximum standardized uptake value predicts outcome after frontline therapy in patients with advanced stage follicular lymphoma

artículo científico publicado en 2019

Predictors of radiation pneumonitis in patients receiving intensity modulated radiation therapy for Hodgkin and non-Hodgkin lymphoma

artículo científico publicado en 2015

Premature closure of a phase II study of bendamustine, mitoxantrone and rituximab for patients with untreated high-risk follicular lymphoma due to severe haematological and infectious toxicity

artículo científico publicado en 2015

Pretreatment SUVmax may influence the clinical benefit of BR over R-CHOP in patients with previously untreated FL

artículo científico publicado en 2020

Prevalence of a Histologic Change of Ocular Adnexal Lymphoma in Patients With a History of Lymphoma

scientific article published on 01 May 2019

Prognostic significance of baseline peripheral absolute neutrophil, monocyte and serum β2-microglobulin level in patients with diffuse large b-cell lymphoma: a new prognostic model.

artículo científico publicado en 2016

Prospective phase II study of rituximab with alternating cycles of hyper-CVAD and high-dose methotrexate with cytarabine for young patients with high-risk diffuse large B-cell lymphoma

artículo científico publicado en 2013

Radiation Therapy as an Effective Salvage Strategy for Secondary CNS Lymphoma.

artículo científico publicado en 2018

Radiation therapy for salivary gland MALT lymphoma: ultra-low dose treatment achieves encouraging early outcomes and spares salivary function

scientific article published on 02 August 2019

Radiation therapy improves survival in patients with testicular diffuse large B-cell lymphoma.

artículo científico publicado en 2017

Response to pembrolizumab and lenalidomide in advanced refractory mycosis fungoides

article

Response-adapted radiation therapy for newly diagnosed primary diffuse large B-cell lymphoma of the CNS treated with methotrexate-based systemic therapy

artículo científico publicado en 2018

Role of the tumor microenvironment in mature B-cell lymphoid malignancies

artículo científico publicado en 2016

Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial

artículo científico publicado en 2013

Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial

artículo científico publicado en 2014

Single-institution experience in the treatment of primary mediastinal B cell lymphoma treated with immunochemotherapy in the setting of response assessment by 18fluorodeoxyglucose positron emission tomography

artículo científico publicado en 2015

Stage I Non-Hodgkin Lymphoma: difference in survival outcome by primary extranodal site of involvement

artículo científico publicado en 2018

Stage I non-Hodgkin lymphoma: no plateau in disease-specific survival ?

scientific article published on 08 January 2019

The combination of ibrutinib and rituximab demonstrates activity in first-line follicular lymphoma

artículo científico publicado en 2020

The prognostic value of interim positron emission tomography scan in patients with classical Hodgkin lymphoma

artículo científico publicado en 2014

The risk of central nervous system relapses in patients with peripheral T-cell lymphoma

artículo científico publicado en 2018

The survival outcome of patients with relapsed/refractory peripheral T-cell lymphoma-not otherwise specified and angioimmunoblastic T-cell lymphoma.

artículo científico publicado en 2016

Ultra-low-dose radiotherapy for definitive management of ocular adnexal B-cell lymphoma

artículo científico publicado en 2017

Ultra-low-dose radiotherapy for definitive management of ocular adnexal B-cell lymphoma

scientific article published on 21 February 2018

Ultra-low-dose radiotherapy for definitive management of ocular adnexal B-cell lymphoma

artículo científico publicado en 2019

Zoledronic acid for prevention of bone loss in patients receiving primary therapy for lymphomas: a prospective, randomized controlled phase III trial

artículo científico publicado en 2012

Lista de obras de

90Y-ibritumomab tiuxetan radiotherapy as first-line therapy for early stage low-grade B-cell lymphomas, including bulky disease

A Prospective Trial of Radiation Therapy Efficacy and Toxicity for Localized Mucosa-associated Lymphoid Tissue (MALT) Lymphoma

A phase 1 trial of alisertib and romidepsin for relapsed/refractory aggressive B-cell and T-cell lymphomas

A phase I study of romidepsin and ifosfamide, carboplatin, etoposide for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma

Additional therapy improves outcomes in completely resected, limited-stage follicular lymphoma

Autologous Stem Cell Transplantation for Large B-cell Lymphoma with Secondary Central Nervous System Involvement

Autologous stem cell transplantation for untreated transformed indolent B-cell lymphoma in first remission: an international, multi-centre propensity-score-matched study

CCL3 and CCL4 are biomarkers for B cell receptor pathway activation and prognostic serum markers in diffuse large B cell lymphoma

Characteristics and management of rash following lenalidomide and rituximab in patients with untreated indolent non-Hodgkin lymphoma

Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas

Characteristics, management, and outcomes of patients with follicular dendritic cell sarcoma.

Clinical and radiologic correlates of neurotoxicity after axicabtagene ciloleucel in large B-cell lymphoma

Clinicopathological characteristics, outcomes and pattern of mutations in patients with follicular lymphoma who progressed on Bruton tyrosine kinase inhibitors.

De novo CD5+ diffuse large B-cell lymphoma, NOS: clinical characteristics and outcomes in rituximab era

Dose adjusted-EPOCH-R and mediastinal disease may improve outcomes for patients with gray-zone lymphoma

Dose-Adjusted EPOCH-R and Mid-Cycle High Dose Methotrexate for Patients with Systemic Lymphoma and secondary CNS Involvement.

Double hit lymphoma: the MD Anderson Cancer Center clinical experience.

Early Stage Extranodal Follicular Lymphoma: Characteristics, Management, and Outcomes

Efficacy of venetoclax in high risk relapsed mantle cell lymphoma (MCL) - outcomes and mutation profile from venetoclax resistant MCL patients

Encouraging activity for R-CHOP in advanced stage nodular lymphocyte-predominant Hodgkin lymphoma

Experience with HSP90 inhibitor AUY922 in patients with relapsed or refractory non-Hodgkin lymphoma

Favorable outcomes with de-escalated radiation therapy for limited-stage nodular lymphocyte-predominant Hodgkin lymphoma

Four-year follow-up of a single arm, phase II clinical trial of ibrutinib with rituximab (IR) in patients with relapsed/refractory mantle cell lymphoma (MCL)

Frontline antibiotic therapy for early-stage Helicobacter pylori-negative gastric MALT lymphoma

Genomic profiles and clinical outcomes of de novo blastoid/pleomorphic MCL are distinct from those of transformed MCL

Hematopoietic recovery and immune reconstitution after axicabtagene ciloleucel in patients with large B-cell lymphoma

High ten-year remission rates following rituximab, fludarabine, mitoxantrone and dexamethasone (R-FND) with interferon maintenance in indolent lymphoma: Results of a randomized Study

Hitting a Moving Target: Successful Management of Diffuse Large B-cell Lymphoma Involving the Mesentery With Volumetric Image-guided Intensity Modulated Radiation Therapy

Impact of Donor Type and Melphalan Dose on Allogeneic Transplantation Outcomes for Patients with Lymphoma

Impact of histologic subtypes and treatment modality among patients with primary central nervous system lymphoma: a SEER database analysis.

Impact of maintenance rituximab in patients with de novo transformed indolent B cell lymphoma

Initial report of a phase II study with R-FND followed by ibritumomab tiuxetan radioimmunotherapy and rituximab maintenance in patients with untreated high-risk follicular lymphoma

Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial

Lenalidomide plus rituximab (R2 ) in previously untreated marginal zone lymphoma: subgroup analysis and long-term follow-up of an open-label phase 2 trial

Lenalidomide, idelalisib, and rituximab are unacceptably toxic in patients with relapsed/refractory indolent lymphoma.

Limited stage grade 3 follicular lymphoma patients can experience favorable outcomes with combined modality therapy

Long Term Follow-Up of Lenalidomide and Rituximab as Initial Treatment of Follicular Lymphoma

Long-Term Remissions of Patients With Follicular Lymphoma Grade 3 Treated With R-CHOP.

Long-term outcomes and mutation profiling of patients with mantle cell lymphoma (MCL) who discontinued ibrutinib

Management strategies and outcomes for very elderly patients with diffuse large B-cell lymphoma.

Maternal and Fetal Outcomes After Therapy for Hodgkin or Non-Hodgkin Lymphoma Diagnosed During Pregnancy.

Nonmyeloablative allogeneic transplantation with or without 90yttrium ibritumomab tiuxetan is potentially curative for relapsed follicular lymphoma: 12-year results.

Outcomes After Reduced-Dose Intensity Modulated Radiation Therapy for Gastric Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma

Paclitaxel, topotecan and rituximab: long term outcomes of an effective salvage programme for relapsed or refractory aggressive B-cell non-Hodgkin lymphoma

Pegylated liposomal doxorubicin replacing conventional doxorubicin in standard R-CHOP chemotherapy for elderly patients with diffuse large B-cell lymphoma: an open label, single arm, phase II trial

Phase 2 trial of bortezomib in combination with rituximab plus hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone alternating with bortezomib, rituximab, methotrexate, and cytarabine for untreated mantle cell lymphoma.

Phase I study of panobinostat plus everolimus in patients with relapsed or refractory lymphoma

Phase II study of HCVIDD/MA in patients with newly diagnosed peripheral T-cell lymphoma

Phase II study of an AKT inhibitor MK2206 in patients with relapsed or refractory lymphoma

Phase-I and randomized phase-II trial of panobinostat in combination with ICE (ifosfamide, carboplatin, etoposide) in relapsed or refractory classical Hodgkin lymphoma.

Pre-treatment maximum standardized uptake value predicts outcome after frontline therapy in patients with advanced stage follicular lymphoma

Predictors of radiation pneumonitis in patients receiving intensity modulated radiation therapy for Hodgkin and non-Hodgkin lymphoma

Premature closure of a phase II study of bendamustine, mitoxantrone and rituximab for patients with untreated high-risk follicular lymphoma due to severe haematological and infectious toxicity

Pretreatment SUVmax may influence the clinical benefit of BR over R-CHOP in patients with previously untreated FL

Prevalence of a Histologic Change of Ocular Adnexal Lymphoma in Patients With a History of Lymphoma

Prognostic significance of baseline peripheral absolute neutrophil, monocyte and serum β2-microglobulin level in patients with diffuse large b-cell lymphoma: a new prognostic model.

Prospective phase II study of rituximab with alternating cycles of hyper-CVAD and high-dose methotrexate with cytarabine for young patients with high-risk diffuse large B-cell lymphoma

Radiation Therapy as an Effective Salvage Strategy for Secondary CNS Lymphoma.

Radiation therapy for salivary gland MALT lymphoma: ultra-low dose treatment achieves encouraging early outcomes and spares salivary function

Radiation therapy improves survival in patients with testicular diffuse large B-cell lymphoma.

Response to pembrolizumab and lenalidomide in advanced refractory mycosis fungoides

Response-adapted radiation therapy for newly diagnosed primary diffuse large B-cell lymphoma of the CNS treated with methotrexate-based systemic therapy

Role of the tumor microenvironment in mature B-cell lymphoid malignancies

Safety and activity of PD1 blockade by pidilizumab in combination with rituximab in patients with relapsed follicular lymphoma: a single group, open-label, phase 2 trial

Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial

Single-institution experience in the treatment of primary mediastinal B cell lymphoma treated with immunochemotherapy in the setting of response assessment by 18fluorodeoxyglucose positron emission tomography

Stage I Non-Hodgkin Lymphoma: difference in survival outcome by primary extranodal site of involvement

Stage I non-Hodgkin lymphoma: no plateau in disease-specific survival ?

The combination of ibrutinib and rituximab demonstrates activity in first-line follicular lymphoma

The prognostic value of interim positron emission tomography scan in patients with classical Hodgkin lymphoma

The risk of central nervous system relapses in patients with peripheral T-cell lymphoma

The survival outcome of patients with relapsed/refractory peripheral T-cell lymphoma-not otherwise specified and angioimmunoblastic T-cell lymphoma.

Ultra-low-dose radiotherapy for definitive management of ocular adnexal B-cell lymphoma

Ultra-low-dose radiotherapy for definitive management of ocular adnexal B-cell lymphoma

Ultra-low-dose radiotherapy for definitive management of ocular adnexal B-cell lymphoma

Zoledronic acid for prevention of bone loss in patients receiving primary therapy for lymphomas: a prospective, randomized controlled phase III trial